Switching Twice With Infliximab Biosimilars Not Linked With IBD Flare Risk
LAS VEGAS — Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study. Patients who switched from infliximab (Remicade) to an infliximab biosimilar, and then switched again to a different biosimilar or back to infliximab, were no more or less likely to experience a disease […]
First Multiple Sclerosis Biosimilar Approved
The first biosimilar for multiple sclerosis (MS) was approved, the FDA announced late Thursday. Natalizumab-sztn (Tyruko) was approved as a biosimilar to natalizumab (Tysabri) injection to treat clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, the agency said. Like its reference biologic, natalizumab-sztn (previously called PB006) also was approved to treat certain adult […]